Effect of resistance training and dark chocolate extract on plasma Myostatin, Follistatin and Myf5 in older adults

Effect of eight weeks resistance training and dark chocolate extract supplementation on plasma Myostatin, Follistatin and Myf5 in older adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016120131180N1

Enrollment

Registered

2017-08-09

Start date

2017-03-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relationship between eight weeks resistance training and the consumption of dark chocolate extract with plasma levels of Myostatin, Follistatin , Myf5 and maximal strength in older adults.

Interventions

Intervention 1: Exercise+Placebo group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-8

Placebo

Exercise+Placebo group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-80% of one repeti

Placebo group: participants of this group received one capsule similar to dark chocolate extract capsules (in terms of smell and shape) daily for 8 weeks, which contained 500 mg starch with 200 ml wa

Exercise+supplement group: participants of this group performed 8 weeks resistance training (at 5 to 6 p.m., three sessions per week, each session took approximately 60 minutes, with 60-80% of one rep

Supplement group: participants of this group consumed one capsule daily, which contained 500 mg dark chocolate extract with 200 ml water, at 4 p.m. for 8 weeks.

Eligibility

Sex/Gender

All

Age

65 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Non-athletic older adults aged 65-75 years; no previous record of any drug or supplement use in the last 1 month; without the experience of regular physical activity in the last year The exclusion criteria: the history of special diseases (such as chronic lung disease (COLD); ischemic heart disease (IHD); valvular heart disease (VHD); hypertension (HTN); Hyperlipoproteinemia (HLP); Hypertrophic Cardiomyopathy (HCM); etc); allergy to dark chocolate; unwillingness; smoking; Mental disorder; muscular or joint injuries (like: Slip disk in the back)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Myostatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.;Follistatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.;Myf5. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.	—

Measure

Time frame

Myostatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.;Follistatin. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.;Myf5. Timepoint: Before starting the intervention, after eight weeks intervention. Method of measurement: Blood sample, ELISA method with special kit.

—

Secondary

Measure	Time frame
Maximal strength. Timepoint: Before and after the intervention. Method of measurement: 1RM formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnoosh Mafi

University of Tehran

farnoosh.mafi@ut.ac.ir+98 28 3365 3117

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026